New active substances authorized in the United Kingdom between 1972 and 1994.

  title={New active substances authorized in the United Kingdom between 1972 and 1994.},
  author={David Jefferys and D. G. B. Leakey and J. A. Lewis and Stephanie R. Payne and Michael D Rawlins},
  journal={British journal of clinical pharmacology},
  volume={45 2},
AIMS The study was undertaken to assemble a list of all new active medicinal substances authorised in the United Kingdom between 1972 and 1994; to assess whether the pattern of introductions had changed; and to examine withdrawal rates and the reasons for withdrawal. METHODS The identities of those new active substances whose manufacturers had obtained Product Licences between 1972 and 1994 were sought from the Medicines Control Agency's product data-base. For each substance relevant… 
Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999*
A descriptive analysis was conducted to evaluate prescription drugs withdrawn from worldwide pharmaceutical markets over the past four decades due to safety reasons, finding that the most common categories of drugs withdrawn were: Non-Steroidal Anti-Inflammatory Drugs, nonnarcotic analgesics, antidepressants, and vasodilators.
The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab.
  • V. Prasad
  • Medicine, Biology
    JAMA internal medicine
  • 2014
Tositumomab was first approved by the US Food and Drug Administration in 2003 for patients with “CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to rituximab and has relapsed following chemotherapy,” according to the prescribing information.
An Assessment of the Publicly Disseminated Evidence of Safety Used in Decisions to Withdraw Medicinal Products from the UK and US Markets
It is rare that evidence other than spontaneous reports is cited in support of drug withdrawals, and the serious implications of product withdrawal mandate the elevation of the level of evidence that supports such public health decisions.
Evaluating the evidence base in pharmacovigilance decision making
A systematic study of the current procedures for handling safety issues in the UK and how these might be improved is reported, revealing the fragmentary nature of information in the public domain and the difficulties of obtaining unpublished information.
Decline in new drug launches: myth or reality? Retrospective observational study using 30 years of data from the UK
There was no significant linear trend in the number of new drugs introduced into the UK from 1982 to 2011 and the purported ‘innovation dip’ is an artefact of the time periods previously studied.
Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012
The sources of evidence supporting pharmacovigilance regulatory activities appear to have changed since implementation of Directive 2010/84/EU and Regulation (EU) No. 1235/2010, which suggests progress towards more rapid regulatory decisions based on more robust evidence.
WITHDRAWN—a resource for withdrawn and discontinued drugs
WITHDRAWN is presented, a resource for withdrawn and discontinued drugs publicly accessible at, which comprises 578 withdrawn or discontinued drugs, their structures, important physico-chemical properties, protein targets and relevant signaling pathways.
Changes in the defined daily dose; CYP2D6/CYP3A metabolism as an indicator for dose-setting problems
This study indicates that CYP2D6 and CYP3A substrates are more likely to require a DDD decrease after granting of market authorisation, however, this effect was diminished by adjusting for period of introduction.


Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety
Since drugs discontinued while a safety question existed represent only 2% of the new chemical entities introduced, it appears that drugs that reach the market under the prevailing regulatory systems are seldom associated with unacceptable toxicity.
Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994.
  • M. Rawlins
  • Medicine
    Journal of the Royal College of Physicians of London
  • 1995
La pharmacovigilance consiste a verifier et s'assurer de la securite des medicaments mis sur le marche, en verifiant ses effets chez l'homme, et en developpant des strategies pour minimiser les